Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Advanced diagnostics in renal mass using optical coherence tomography: a preliminary report.

Barwari K, de Bruin DM, Cauberg EC, Faber DJ, van Leeuwen TG, Wijkstra H, de la Rosette J, Laguna MP.

J Endourol. 2011 Feb;25(2):311-5. doi: 10.1089/end.2010.0408. Epub 2011 Jan 15.

PMID:
21235359
2.

Differentiation between normal renal tissue and renal tumours using functional optical coherence tomography: a phase I in vivo human study.

Barwari K, de Bruin DM, Faber DJ, van Leeuwen TG, de la Rosette JJ, Laguna MP.

BJU Int. 2012 Oct;110(8 Pt B):E415-20. doi: 10.1111/j.1464-410X.2012.11197.x. Epub 2012 May 10.

3.

Feasibility of optical coherence tomography imaging to characterize renal neoplasms: limitations in resolution and depth of penetration.

Linehan JA, Bracamonte ER, Hariri LP, Sokoloff MH, Rice PS, Barton JK, Nguyen MM.

BJU Int. 2011 Dec;108(11):1820-4. doi: 10.1111/j.1464-410X.2011.10282.x. Epub 2011 May 18.

4.

Image-guided biopsy-diagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up.

Somani BK, Nabi G, Thorpe P, N'Dow J, Swami S, McClinton S; Aberdeen Academic and Clinical Urological Surgeons (ABACUS) Group.

Eur Urol. 2007 May;51(5):1289-95; discussion 1296-7. Epub 2006 Oct 25.

PMID:
17081679
5.

Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients.

Jeon HG, Lee SR, Kim KH, Oh YT, Cho NH, Rha KH, Yang SC, Han WK.

Urology. 2010 Sep;76(3):574-9. doi: 10.1016/j.urology.2009.11.082. Epub 2010 Mar 29.

PMID:
20303148
6.

Preoperative imaging in renal cell cancer.

Heidenreich A, Ravery V; European Society of Oncological Urology.

World J Urol. 2004 Nov;22(5):307-15. Epub 2004 Jul 30. Review.

PMID:
15290202
7.

Diffusion-weighted imaging using 3.0 T MRI as a possible biomarker of renal tumors.

Mirka H, Korcakova E, Kastner J, Hora M, Hes O, Hosek P, Ferda J.

Anticancer Res. 2015 Apr;35(4):2351-7.

PMID:
25862900
8.

Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).

Wechsel HW, Petri E, Bichler KH, Feil G.

Anticancer Res. 1999 Jul-Aug;19(4A):2583-90.

PMID:
10470199
9.

Differentiation of clear from non-clear cell renal cell carcinoma using CT washout formula.

Kopp RP, Aganovic L, Palazzi KL, Cassidy FH, Sakamoto K, Derweesh IH.

Can J Urol. 2013 Jun;20(3):6790-7.

PMID:
23783049
10.

Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications.

Kruck S, Hennenlotter J, Vogel U, Schilling D, Gakis G, Hevler J, Kuehs U, Stenzl A, Schwentner C.

BJU Int. 2012 Feb;109(4):634-8. doi: 10.1111/j.1464-410X.2011.10392.x. Epub 2011 Jun 28.

11.

Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential.

Huber J, Winkler A, Jakobi H, Bruckner T, Roth W, Hallscheidt P, Daneshvar K, Hohenfellner M, Pahernik S.

Urol Oncol. 2014 Jan;32(1):37.e1-6. doi: 10.1016/j.urolonc.2013.02.016. Epub 2013 Apr 12.

PMID:
23587431
12.

Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.

Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, Genega EM, Rofsky NM, Alsop DC, Pedrosa I.

Radiology. 2012 Dec;265(3):799-808. doi: 10.1148/radiol.12112260. Epub 2012 Oct 9.

13.

Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients.

Fujii Y, Komai Y, Saito K, Iimura Y, Yonese J, Kawakami S, Ishikawa Y, Kumagai J, Kihara K, Fukui I.

Urology. 2008 Sep;72(3):598-602. doi: 10.1016/j.urology.2008.04.054. Epub 2008 Jul 23.

PMID:
18649929
14.

Integrated optical coherence tomography and optical coherence microscopy imaging of ex vivo human renal tissues.

Lee HC, Zhou C, Cohen DW, Mondelblatt AE, Wang Y, Aguirre AD, Shen D, Sheikine Y, Fujimoto JG, Connolly JL.

J Urol. 2012 Feb;187(2):691-9. doi: 10.1016/j.juro.2011.09.149. Epub 2011 Dec 16.

16.

Pretreatment differentiation of renal cell carcinoma subtypes by CT: the influence of different tumor enhancement measurement approaches.

Zokalj I, Marotti M, Kolarić B.

Int Urol Nephrol. 2014 Jun;46(6):1089-100. doi: 10.1007/s11255-013-0631-8. Epub 2014 Jan 1.

PMID:
24381132
17.

Quantitative measurement of attenuation coefficients of bladder biopsies using optical coherence tomography for grading urothelial carcinoma of the bladder.

Cauberg EC, de Bruin DM, Faber DJ, de Reijke TM, Visser M, de la Rosette JJ, van Leeuwen TG.

J Biomed Opt. 2010 Nov-Dec;15(6):066013. doi: 10.1117/1.3512206.

PMID:
21198187
18.

Diagnostic yield of renal biopsy immediately prior to laparoscopic radiofrequency ablation: a multicenter study.

Kyle CC, Wingo MS, Carey RI, Leveillee RJ, Bird VG.

J Endourol. 2008 Oct;22(10):2291-3. doi: 10.1089/end.2008.9717.

PMID:
18937593
19.

Three-Tesla dynamic contrast-enhanced MRI: a critical assessment of its use for differentiation of renal lesion subtypes.

Sevcenco S, Ponhold L, Javor D, Kuehhas FE, Mauermann J, Miernik A, Schoenthaler M, Baltzer PA.

World J Urol. 2014 Feb;32(1):215-20. doi: 10.1007/s00345-013-1177-1. Epub 2013 Oct 9.

PMID:
24105251
20.

Transitional cell and clear cell renal carcinoma: differentiation of distinct histological types with multiphase CT.

Bata P, Tarnoki DL, Tarnoki AD, Novak PK, Gyebnar J, Kekesi D, Szendroi A, Fejer B, Szasz AM, Nyirady P, Karlinger K, Berczi V.

Acta Radiol. 2014 Nov;55(9):1112-9. doi: 10.1177/0284185113510493. Epub 2013 Nov 15.

PMID:
24243889
Items per page

Supplemental Content

Write to the Help Desk